2 unknown, 1 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
Follow Chronic Lymphocytic Leukemia Research Consortium: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) Lenalidomide and Rituximab - Chronic Lymphocytic Leukemia, CLL | Phase 2 | Unknown | Chronic Lymphocytic Leukemia Research Consortium | 80 | 2008-02-01 | 2010-09-10 |
| Kinetic Biomarker for Chronic Lymphocytic Leukemia Prognosis Chronic Lymphocytic Leukemia | Completed | KineMed | 150 | 2005-07-01 | 2011-02-28 | |
| Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy Alemtuzumab (Campath-1H) - B-Cell Chronic Lymphocytic Leukemia | Phase 2 | Unknown | Chronic Lymphocytic Leukemia Research Consortium | 31 | 2003-12-01 | 2008-12-03 |
Leukemia, Lymphocytic, Chronic, B-Cell (3) · Bronchiolitis Obliterans Syndrome (1) · Leukemia (1) · Neoplasms (1)
Alemtuzumab (1) · Lenalidomide (1) · Rituximab (1)
United States (3)
Danelle F James, M.D. (1) · Gregory Hayes, Ph.D. (1) · Thomas J Kipps, M.D., Ph.D (1) · Thomas Kipps, MD, PhD (1)